VitaSpring Biomedical Reports No Revenue and Increased Losses for Three and Nine Months Ending October 31, 2024

VitaSpring Biomedical Co., Ltd. has reported its financial results for the three and nine months ending October 31, 2024, revealing a continued lack of revenue generation. The company reported no revenues for both the three-month and nine-month periods, consistent with the previous year. Operating expenses for the three months ended October 31, 2024, were $196,292, a decrease from $234,980 in the same period of 2023. For the nine months, operating expenses also decreased to $631,785 from $893,164 year-over-year. The net loss for the three months was $196,292, compared to a loss of $234,980 in the prior year, while the nine-month net loss improved to $631,785 from $893,164.

The company's balance sheet as of October 31, 2024, shows total assets of $58,382, a significant decline from $137,342 as of January 31, 2024. Current assets increased to $41,787 from $23,627, primarily due to an increase in prepaid expenses. However, total liabilities rose to $3,930,445 from $3,487,531, leading to a stockholders' deficit of $3,872,063, compared to $3,350,189 at the end of the previous fiscal period. The increase in liabilities is attributed to advances from related parties, which rose to $776,415 from $425,482.

VitaSpring has not made any significant strategic developments such as acquisitions or product launches during the reported period. The company continues to focus on its core mission of developing stem cell applications in regenerative medicine, although it has not generated revenue from these efforts. The company has maintained a consistent employee headcount of 207,030,030 shares outstanding, with no new stock issuances reported during the period. The lack of revenue generation and the ongoing operational losses raise concerns about the company's ability to sustain its operations without additional financing.

Management has indicated that the company is actively seeking additional capital through equity financing and strategic partnerships to fund its operations. As of October 31, 2024, the company had a minimal cash balance of $2,062, which is insufficient to cover its liabilities and operational expenses for more than a month. The company’s accumulated deficit has increased to $5,138,366, reflecting ongoing financial challenges. The management's outlook remains cautious, emphasizing the need for external funding to continue operations and meet financial obligations.

In summary, VitaSpring Biomedical Co., Ltd. continues to face significant financial challenges, with no revenue generation and increasing operational losses. The company is exploring avenues for additional capital to support its ongoing efforts in the regenerative medicine sector, but its current financial position raises substantial doubt about its ability to continue as a going concern.